Home  |  About  |  PCSK9  |  News  |  Commentary  |  Trials  |  Videos  |  Resources  |  Contact News from AHA Scientific Sessions 2016 Late Breaking Lipid Trials: Future Bodes Bright for PCSK9 GLAGOV: Greater LDL-C lowering with the PCSK9 inhibitor evolocumab on a statin background leads to greater plaque regression. View the results here » PCSK9 Forum Editors discuss the implications of GLAGOV in this Editorial Read the report » ORION-1: PCSK9 RNA interference agent inclisiran (previously known as ALN-PCSsc) continues to look good, with durable LDL-C lowering over 4-6 months. View the results here » New and updated edition of our popular therapeutic guide A second edition of the free introductory guide: PCSK9 Inhibition - New Therapies in Cardiovascular Risk Reduction is now available on the Forum’s website. This very popular book has been updated with the latest information discussing the biology and therapeutic potential of PCSK9 inhibition. Read online » Download now » Forward to colleagues »   Questions & Answers Read the full answer and other questions on the PCSK9 Forum » Like us on Facebook For the latest updates, PCSK9 news and analysis. Follow us on Twitter Hot topics, news and conference reports. YouTube Channel For videos, interviews and webcasts from leading experts. Educational Partners and Supporters Copyright PCSK9 Forum 2016. Please click here to unsubscribe from future mailings.